F20-F29
Conditions
Interventions
Group 1: Patients with schizophrenia spectrum disorders
Suitable patients are informed about the study and possibly included. After completing clinical interviews (SCID-V-CV, Module C Differential Dia
Positive and Negative Syndrome Scale, PANSS
The Calgary Depression Scale for Schizophrenia, CDSS
Extrapyramidal Symptom Rating Scale, ESRS
Salpêtrière Retardation Rating Scale, SRRS
Drug Attitude Inventory, DAI-10) and a 3D movement analysis, patients are treated either with biperiden or by reducing medication as part of routine clinical practice (intervention is not part of the
Salpêtrière Retardation Rating Scale, SRRS) and the 3D movement analysis are conducted on a single day. In total 1 examination.
Sponsors
LVR-Klinikum Düsseldorf
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Psychiatrically healthy study participants without illness affecting motor function - Patients receiving pharmacotherapy for a schizophrenic disorder (ICD-10: F2X) for whom either symptomatic pharmacotherapy or a dose reduction of antipsychotic therapy is indicated due to EPS. - Ability to understand the study procedure and the handling of personal data - Written informed consent: An informed consent form must be personally signed and dated by the subject.
Exclusion criteria
Exclusion criteria: - Presence of neurological or mental disorders that are not assumed to be a cause for the psychosis, but which significantly impair motor function, e.g. dementia, severe arthritis, existing drug/alcohol abuse or stroke. Due to the high comorbidity of mental disorders, such conditions are considered in the analyses but are not a strict exclusion criterion. - Inability to give informed consent - Pregnancy - CDSS score >6
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the analysis is to compare the motion tracking movement data with traditional clinical assessment scales used as standard procedures in routine clinical practice. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome is to differentiate between psychosis-associated movement disorders and drug-induced movement disorders. | — |
Countries
Germany
Contacts
Public ContactLeonhard Schilbach
LVR-Klinikum Düsseldorf
Outcome results
None listed